GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:01 2026-03-06 am EST			5-day change	1st Jan Change
2,038.00 ^GBX	-1.83%		-7.41%	+11.70%

Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 05	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE

Quest Diagnostics Incorporated announces an Increase in Equity Buyback

Published on 02/10/2026 at 11:01 am EST

S&P Capital IQ

GSK PLC

-1.83%

QUEST DIAGNOSTICS INCORPORATED

-2.34%

On February 10, 2026, the company announced an increase in its equity buyback plan by $1,000 million, thereby increasing the total authorization to $10,500 million.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	2,038.00GBX	-1.83%	-7.41%	109B
	QUEST DIAGNOSTICS INCORPORATED	199.21USD	-2.34%	-5.99%	21.89B

Latest news about GSK plc

Mar. 05	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
Mar. 05	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE
Mar. 04	When Talk of Talks Moves Markets
Mar. 04	Remember 2022
Mar. 03	Rosebank fundraise; Surface Transforms loses GM deal	AN
Mar. 03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
Mar. 03	Fda approves first generic of Flovent HFA for treatment of asthma	RE
Mar. 03	GSK plc completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. for $1.7 billion.	CI
Mar. 03	GSK Completes Purchase of RAPT Therapeutics	MT
Mar. 03	GSK Wraps Up $2.2 Billion Deal to Buy US-based Rapt Therapeutics	MT
Mar. 02	A Very Dangerous Gamble
Mar. 02	GSK : Sell rating from JP Morgan	ZD
Mar. 02	Price targets raised for BP and Shell	AN
Mar. 02	A Leap into the Unknown
Feb. 27	EU regulator backs approval for Moderna's combined COVID and flu vaccine	RE

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

More about the company